OBJECTIVE: To examine whether genetic, environmental, and serologic rheumatoid arthritis (RA) risk factors are associated with inflammatory joint signs in a cohort of first-degree relatives (FDRs) of RA patients. METHODS: We evaluated RA risk factors and inflammatory joint signs in a prospective cohort of FDRs without RA in the Studies of the Etiology of RA. Genetic factors included 5 HLA-DRB1 shared epitope alleles and 45 RA-associated single-nucleotide polymorphisms; loci were combined using genetic risk scores weighted by RA risk. Environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies were assessed at baseline. Physical examination was performed at baseline and 2-year follow-up, by observers who were blinded with regard to autoantibody status, to assess inflammatory joint signs as tender or swollen joints at sites typical for RA. Logistic regression was performed to evaluate associations of genetic, environmental, and serologic factors with inflammatory joint signs. RESULTS: We analyzed 966 non-Hispanic white FDRs at baseline and 262 at 2-year follow-up after excluding those with inflammatory joint signs at baseline. The mean ± SD age was 47.2 ± 15.5 years, 71% were female, and 55% were shared epitope positive. Smoking >10 pack-years was associated with inflammatory joint signs at baseline (odds ratio [OR] 1.89 [95% confidence interval (95% CI) 1.26-2.82]) and at 2 years (OR 2.66 [95% CI 1.01-7.03]), compared to never smokers. There was a significant interaction between smoking and age with regard to risk of inflammatory joint signs (P = 0.02). FDRs younger than 50 years with >10 pack-years had the highest risk of inflammatory joint signs (OR 4.39 [95% CI 2.22-8.66], compared to never smokers younger than 50 years). CONCLUSION: In a high-risk cohort of FDRs, smoking and age were associated with both prevalent and incident inflammatory joint signs at sites typical for RA. Further prospective investigations of the factors affecting the transitions between preclinical RA phases are warranted.
OBJECTIVE: To examine whether genetic, environmental, and serologic rheumatoid arthritis (RA) risk factors are associated with inflammatory joint signs in a cohort of first-degree relatives (FDRs) of RA patients. METHODS: We evaluated RA risk factors and inflammatory joint signs in a prospective cohort of FDRs without RA in the Studies of the Etiology of RA. Genetic factors included 5 HLA-DRB1 shared epitope alleles and 45 RA-associated single-nucleotide polymorphisms; loci were combined using genetic risk scores weighted by RA risk. Environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies were assessed at baseline. Physical examination was performed at baseline and 2-year follow-up, by observers who were blinded with regard to autoantibody status, to assess inflammatory joint signs as tender or swollen joints at sites typical for RA. Logistic regression was performed to evaluate associations of genetic, environmental, and serologic factors with inflammatory joint signs. RESULTS: We analyzed 966 non-Hispanic white FDRs at baseline and 262 at 2-year follow-up after excluding those with inflammatory joint signs at baseline. The mean ± SD age was 47.2 ± 15.5 years, 71% were female, and 55% were shared epitope positive. Smoking >10 pack-years was associated with inflammatory joint signs at baseline (odds ratio [OR] 1.89 [95% confidence interval (95% CI) 1.26-2.82]) and at 2 years (OR 2.66 [95% CI 1.01-7.03]), compared to never smokers. There was a significant interaction between smoking and age with regard to risk of inflammatory joint signs (P = 0.02). FDRs younger than 50 years with >10 pack-years had the highest risk of inflammatory joint signs (OR 4.39 [95% CI 2.22-8.66], compared to never smokers younger than 50 years). CONCLUSION: In a high-risk cohort of FDRs, smoking and age were associated with both prevalent and incident inflammatory joint signs at sites typical for RA. Further prospective investigations of the factors affecting the transitions between preclinical RA phases are warranted.
Authors: Jeffrey A Sparks; Chia-Yen Chen; Xia Jiang; Johan Askling; Linda T Hiraki; Susan Malspeis; Lars Klareskog; Lars Alfredsson; Karen H Costenbader; Elizabeth W Karlson Journal: Ann Rheum Dis Date: 2014-03-31 Impact factor: 19.103
Authors: Henrik Källberg; Bo Ding; Leonid Padyukov; Camilla Bengtsson; Johan Rönnelid; Lars Klareskog; Lars Alfredsson Journal: Ann Rheum Dis Date: 2010-12-13 Impact factor: 19.103
Authors: Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers Journal: J Clin Invest Date: 2006-04 Impact factor: 14.808
Authors: Lillian Barra; Vivian Bykerk; Janet E Pope; Boulos P Haraoui; Carol A Hitchon; J Carter Thorne; Edward C Keystone; Gilles Boire Journal: J Rheumatol Date: 2013-02-01 Impact factor: 4.666
Authors: Yang Hu; Karen H Costenbader; Xiang Gao; May Al-Daabil; Jeffrey A Sparks; Daniel H Solomon; Frank B Hu; Elizabeth W Karlson; Bing Lu Journal: Am J Clin Nutr Date: 2014-07-16 Impact factor: 7.045
Authors: Wouter H Bos; Lotte A van de Stadt; Azita Sohrabian; Johan Rönnelid; Dirkjan van Schaardenburg Journal: Arthritis Res Ther Date: 2014-03-17 Impact factor: 5.156
Authors: Julia A Ford; Xinyi Liu; Allison A Marshall; Alessandra Zaccardelli; Maria G Prado; Charlene Wiyarand; Bing Lu; Elizabeth W Karlson; Peter H Schur; Kevin D Deane; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2019-12 Impact factor: 4.794
Authors: Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Robert Vassallo; John M Davis Journal: Arthritis Rheumatol Date: 2019-07-01 Impact factor: 10.995
Authors: Ahmad M Al-Bashaireh; Linda G Haddad; Michael Weaver; Debra Lynch Kelly; Xing Chengguo; Saunjoo Yoon Journal: J Environ Public Health Date: 2018-07-11
Authors: Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers Journal: Best Pract Res Clin Rheumatol Date: 2017-09-18 Impact factor: 4.098
Authors: Jeffrey A Sparks; Tzu-Chieh Lin; Carlos A Camargo; Medha Barbhaiya; Sara K Tedeschi; Karen H Costenbader; Benjamin A Raby; Hyon K Choi; Elizabeth W Karlson Journal: Semin Arthritis Rheum Date: 2017-09-18 Impact factor: 5.532
Authors: Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Curr Rheumatol Rev Date: 2019
Authors: Jeffrey A Sparks; Shun-Chiao Chang; Uyen-Sa D T Nguyen; Medha Barbhaiya; Sara K Tedeschi; Bing Lu; Karen H Costenbader; Yuqing Zhang; Hyon K Choi; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2017-12-15 Impact factor: 4.794
Authors: D Alpizar-Rodriguez; Laure Brulhart; Ruediger B Mueller; Burkhard Möller; Jean Dudler; Adrian Ciurea; Ulrich A Walker; Ines Von Mühlenen; Diego Kyburz; Pascal Zufferey; Michael Mahler; Sylvette Bas; Danielle Gascon; Céline Lamacchia; Pascale Roux-Lombard; Kim Lauper; Michael J Nissen; Delphine S Courvoisier; Cem Gabay; Axel Finckh Journal: Clin Rheumatol Date: 2017-01-21 Impact factor: 2.980